Cisplatin is a highly effective cancer chemotherapy agent. However, acquired resistance currently limits the clinical utility of this drug. The human high affinity copper importer, hCtr1, and its yeast and murine orthologues have been shown to mediate the uptake of cisplatin. This transporter is located at the plasma membrane under low copper conditions, and excess copper concentrations stimulate its endocytosis and degradation. In this study we further examined the link between cisplatin and hCtr1 by examining whether cisplatin can also stimulate the endocytosis and degradation of hCtr1. The steady-state location of hCtr1 and its endocytosis from the plasma membrane were not altered by cisplatin treatment. Unexpectedly, cisplatin treatment of a cell line expressing hCtr1 revealed the time-and concentration-dependent appearance of a stable hCtr1 multimeric complex, consistent with a homotrimer, which was not observed following copper treatment of these same cells. Mutagenesis studies identified two methionine-rich clusters in the extracellular amino-terminal region of hCtr1 that were required for stabilization of the hCtr1 multimer by cisplatin, suggesting that these sequences bind cisplatin and form crosslinks between hCtr1 polypeptides. Treatment with the metal chelator dimethyldithiocarbamate disassembled the hCtr1 multimer following cisplatin exposure, suggesting that platinum was an integral component of this complex. These studies provide the first evidence for a direct interaction between cisplatin and the hCtr1 protein and establish that cisplatin and copper have distinct biochemical consequences on this transporter.
Copper is an essential metal for various metabolic processes including oxidative phosphorylation, catecholamine biosynthesis, antioxidant defense, pigmentation, and iron homeostasis (1) . Like all essential metals, copper is potentially toxic at elevated concentrations, and homeostatic mechanisms have evolved to provide sufficient copper for metabolic requirements while avoiding copper toxicity. Copper homeostasis is accomplished through the action of copper transporters and intracellular copper chaperones. High affinity copper uptake at the plasma membrane in humans is mediated by the hCtr1 protein (2, 3) , which has highly conserved orthologues in yeast (4, 5) , insects (6) , and plants (6) . Members of the Ctr1 family have three putative membrane-spanning domains, and studies on human Ctr1 (hCtr1) and yeast Ctr1 (yCtr1) suggest that these proteins assemble as homodimers and -trimers (3, 4) . Recent studies have also shown that elevated copper concentrations stimulate the endocytosis and degradation of hCtr1 and yCtr1 proteins (7) (8) (9) . This process is likely a homeostatic mechanism that prevents the over-accumulation of potentially toxic copper. Once in the cytoplasm, copper is delivered to specific destinations via one of three copper chaperones, CCS, COX17, or ATOX1 (1) . CCS delivers copper to superoxide dismutase, COX17 delivers copper to cytochrome c oxidase, and ATOX1 transfers copper to one of two copper-transporting ATPases, ATP7A or ATP7B. The ATP7A and ATP7B proteins are located in the trans-Golgi network and are required to deliver copper into secretory compartments for the assembly of copper-requiring enzymes (10 -13) .
An unexpected connection has recently been discovered between the copper transporters and the accumulation of, and resistance to, the chemotherapy drug cisplatin (cis-diamminedichloroplatinum (DDP)). 1 The ectopic expression of ATP7A and ATP7B in cultured cells is associated with DDP resistance (14, 15) , and the endogenous ATP7A or ATP7B proteins are over-expressed in certain DDP-resistant cell lines (16 -18) . It is thought that these copper transporters confer DDP resistance by transporting DDP into vesicular compartments, thereby sequestering the drug from cytotoxic targets (19) .
Recent studies have also implicated a role for the Ctr1 copper importer in the uptake of DDP. Deletion of yCtr1 in yeast or mCtr1 in mouse embryonic fibroblasts confers DDP resistance. This is associated with reduced uptake of the drug (20, 21) , consistent with a role for Ctr1 in cisplatin uptake. In support of this proposed role, studies have demonstrated that the overexpression of human hCtr1 protein in ovarian carcinoma cell lines results in the increased uptake of DDP (22) . Interestingly, however, DDP toxicity is not significantly increased in these hCtr1-overexpressing cells, and the internalized DDP does not have ready access to the DNA, suggesting that the DDP imported by hCtr1 is prevented from reaching cytotoxic targets (22) . Despite a role for hCtr1 in DDP uptake, it remains unclear whether the drug can also exert regulatory control over the location and trafficking of the hCtr1 protein.
In this study, we further examined the link between DDP and hCtr1 by testing whether DDP can mimic the ability of copper to stimulate the endocytosis and degradation of hCtr1 in human cells. Rather than stimulating hCtr1 endocytosis, DDP treatment resulted in the stabilization of a high molecular weight complex of the hCtr1 protein that was consistent with a homotrimer. This DDP-mediated appearance of the hCtr1 multimer was reversible upon chelation of platinum from the complex, and mutagenesis studies identified two extracellular methionine-rich clusters that were essential for this process. These findings suggest that the uptake of DDP is associated with the formation of a stable homotrimer that is stabilized via interactions between DDP and the methionine-rich clusters.
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents-The human embryonic kidney cell line, HEK293, was cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum under 5% CO 2 . This basal medium contains ϳ1 M copper. HEK293 cells stably transfected with the pcDNA3.1 empty vector or the same vector harboring the wild type or M1/M2 mutant hCTR1 cDNAs have been described previously (7, 8) . DDP, oxaliplatin, and carboplatin were purchased from Sigma and freshly prepared prior to each experiment. Copper was supplied to the growth medium as CuCl 2 . In vitro cross-links were generated by treating cell lysates with 100 mM ethylene glycol bis(succinimidylsuccinate) (EGS) (Sigma) as described previously (3) . The affinity-purified anti-myc antibody (clone 9E10) was purchased from Roche Applied Science.
Immunofluorescence Microscopy-Cells were grown on sterile glass coverslips coated with poly-L-lysine (Sigma) and treated with DDP and/or copper as indicated. After rinsing twice with 1 ml of ice-cold phosphate-buffered saline (PBS), cells were fixed for 10 min at 25°C using 4% paraformaldehyde in PBS and then permeabilized with 0.1% Triton X-100 in PBS for 5 min. Cells were blocked for 1 h with 1% bovine serum albumin and 3% skim milk in PBS and probed with the anti-myc antibodies (10 g/ml) followed by Alexa 488 antimouse antibodies (1:1000).
Immunoblots and Endocytosis Assays-For immunoblot detection of the total hCtr1 protein, de novo protein synthesis was inhibited by pretreating cells for 30 min with 100 g/ml cycloheximide, which was subsequently maintained throughout copper and DDP treatments. This allowed changes in levels of monomeric hCtr1 to be observed without the confounding effects of new protein synthesis. Cells cultured in 6-well trays were scraped into ice-cold PBS and pelleted by centrifugation. After several washes in ice-cold PBS, the cells were lysed for 20 min on ice in buffer containing 62.5 mM Tris-HCl (pH 7.4), 1% Triton X-100, 1 mM EDTA, and protease inhibitor mixture (Roche Applied Science). Samples were centrifuged for 10 min at 16,000 ϫ g, and 20 g of protein lysates were separated using non-reducing 4 -20% SDS-PAGE, transferred to nitrocellulose membranes, and detected by chemiluminescence using anti-myc antibodies (1:1000) followed by anti-mouse antibodies conjugated to horseradish peroxidase (HRP) (1:5000). The endocytosis of hCtr1-myc protein was determined by measuring the uptake of anti-myc antibodies added to the culture medium of stably transfected HEK293 cells, as described previously (8) . Briefly, cells in 6-well trays were incubated in the presence of 10 g/ml anti-myc antibodies for 5 min at 37°C in basal medium or media containing the indicated concentrations of copper and/or DDP. Cells were washed twice with PBS on ice, and surface-bound antibodies were removed by three washes in ice-cold acidic buffer (100 mM glycine, 20 mM magnesium acetate, 50 mM potassium chloride, pH 2.2). Cells were harvested by scraping into ice-cold PBS and pelleted by centrifugation at 1000 ϫ g. The cell pellets were solubilized in lysis buffer (above), and 20 g of lysates containing internalized anti-myc antibodies were separated using 4 -20% SDS-PAGE, transferred to nitrocellulose membranes, and detected by chemiluminescence using HRP-conjugated anti-mouse antibodies.
RESULTS
Several studies have suggested that the yeast, murine, and human Ctr1 orthologues function in the uptake of DDP (22) . To further explore the connection between DDP and hCtr1, we tested whether DDP could mimic the ability of copper to stimulate the endocytosis of a functional myc-tagged human hCtr1 protein stably expressed in HEK293 cells (3, 8) . As expected, the exposure of cells to 20 M copper for 1 h altered the distribution of hCtr1-myc from the plasma membrane to a predominantly vesicular localization (Fig. 1, compare A with B) . A longer exposure of 2 h in the presence of elevated copper reduced the intensity of this vesicular staining (Fig. 1C) , consistent with the degradation of hCtr1-myc by high copper concentrations reported previously (8) . However, when cells were exposed to 200 M DDP for 1 or 2 h, the location of the hCtr1-myc protein was unchanged from the plasma membrane distribution observed in untreated cells (Fig. 1, D and E). Longer DDP exposure times (6 h) and higher DDP concentrations (up to 1 mM) failed to alter the location of hCtr1-myc (data not shown). These data suggested that the location of hCtr1 was not altered in response to DDP. We then tested whether a pretreatment of cells with DDP could block the relocalization of hCtr1 by copper. Pretreating cells with 200 M DDP for 1 h failed to block the copper-induced redistribution of hCtr1 to vesicles when 20 M copper was subsequently added to the DDP-containing media (Fig. 1F ). These data suggest that the steady-state location of hCtr1 is not affected by DDP, and that a 10-fold molar excess of DDP does not inhibit copper-stimulated endocytosis.
To more rigorously test the effect of DDP on the location of hCtr1, we examined whether the endocytosis of hCtr1 was altered by DDP. The extracellular location of the myc tag permits analysis of hCtr1-myc endocytosis by the measurement of the internalization of anti-myc antibodies from the media by living cells expressing this protein. This method has been used to define the kinetics, sensitivity, and metal specificity of copper-stimulated endocytosis of hCtr1-myc (8, 23) . As expected, copper was found to stimulate endocytosis of hCtr1-myc, as was evident by the increased internalization of anti-myc antibodies by copper-treated HEK/hCtr1-myc cells relative to untreated cells ( Fig. 2A, lanes 3 and 4) . However, in DDP-treated cells, there was no change in the extent of hCtr1-myc endocytosis relative to untreated cells ( Fig. 2A, lanes 3 and 5) . failed to block copper-stimulated endocytosis of hCtr1 after the addition of 20 M copper to the DDP-containing media ( Fig. 2A,  lane 6 ). There was no uptake of anti-myc antibodies by vectortransfected control cells in basal medium or medium containing 100 M copper ( Fig. 2A, lanes 1 and 2) , indicating that the uptake of antibodies was dependent on the hCtr1-myc protein.
Control experiments demonstrated that neither DDP nor copper in the media affected the binding of anti-myc antibodies to the hCtr1-myc protein at the surface of cells (data not shown). Further studies were undertaken to test whether a high DDP concentration affects the sensitivity of hCtr1 endocytosis to low micromolar copper concentrations that are closer to the K m for copper uptake activity (ϳ2 M copper) (3, 24) . A pre-exposure for 1 h to 200 M DDP did not alter the copper-stimulated endocytosis of hCtr1-myc in response to low micromolar copper concentrations compared with untreated cells (Fig. 2B , compare lanes 6 -10 with lanes [1] [2] [3] [4] [5] . These findings independently confirmed the immunofluorescence studies and suggested that DDP does not stimulate the endocytosis of the hCtr1-myc protein or block the ability of copper to induce this process.
We then examined the possibility that DDP may cause the degradation of the hCtr1 protein. The hCtr1 protein migrates as a 35-kDa monomer and a 70-kDa dimer in non-reducing SDS gels (3, 24, 25) . Both of these expected sizes for hCtr1-myc were observed by immunoblot analysis of HEK/hCtr1-myc cells using anti-myc antibodies (Fig. 3, lane 2, ovals) . A cross-reacting endogenous protein was also detected by the anti-myc antibody in HEK293 cells (Fig. 3, lane 1, asterisk) as reported previously (7, 8) . The exposure of cells to elevated copper levels resulted in the degradation of hCtr1-myc, as indicated by the marked diminution of both 35-and 70-kDa bands (Fig. 3, lane 3) . Surprisingly, treating HEK/hCtr1-myc cells with increasing concentrations of DDP resulted in the appearance of a slower migrating complex of 110 kDa with the concomitant diminution of the 35-and 70-kDa species (Fig. 3, lanes 4 -8) . At both 10 and 50 M DDP concentrations, the 110-kDa hCtr1 multimer was clearly visible as a double band, suggesting that various conformations may exist for this complex. The apparent molecular weight of this complex was close to that predicted for a homotrimeric form of hCtr1, suggesting that DDP may stabilize this trimeric form by forming cross-links between hCtr1 polypeptides.
To further characterize the stabilization of the hCtr1 multimer by DDP, a time course analysis of this process was undertaken. The exposure of HEK/hCtr1-myc cells to DDP for 30 s was sufficient to allow detection of the 110-kDa hCtr1 multimer (Fig. 4, lane 2) , and saturation was observed between 30 and 60 min (Fig. 4, lanes 6 and 7) . Interestingly, the multimerization of hCtr1 was also observed when DDP was added to cells that had been pre-cooled to 4°C (Fig. 4, lane 9) , a condition that is known to block both hCtr1-dependent copper transport activity and endocytosis of the protein (3, 8) . This observation suggested that the stabilization of the hCtr1 multimer does not require the uptake of DDP or the endocytosis of hCtr1 and therefore may involve DDP-mediated cross-links between regions of hCtr1 proteins that are exposed at the cell surface.
If stabilizing the hCtr1 multimer did involve DDP-mediated cross-links, we predicted that such a process would be reversible upon extraction of DDP from the protein complex. The metal chelator diethydithiocarbamate (DDTC) was tested for the ability to reverse DDP-induced hCtr1 multimerization. This agent is a strong chelator of platinum compounds and has been shown to protect against DDP-induced cytotoxicity (26 -28) . HEK/hCtr1-myc cells were initially exposed to 200 M DDP 8) . Total protein extracts were prepared from cells, separated by SDS-PAGE, and transferred to nitrocellulose membranes. hCtr1-myc protein was detected using the affinity purified anti-myc antibody followed by anti-mouse secondary antibodies conjugated to HRP. The predicted positions of monomeric, dimeric, and trimeric hCtr1 complexes are indicated (ovals). The asterisk indicates a nonspecific crossreacting protein endogenous in HEK293 cells. Tubulin protein levels in each sample are shown in the lower panel to indicate protein loading.
to generate the multimeric hCtr1 complex. The protein lysates from these cells were then exposed to a range of DDTC concentrations prior to analysis of hCtr1 by Western blotting. A dosedependent disassembly of the hCtr1 complex was observed following the exposure to DDTC, as indicated by the loss of the 110-kDa hCtr1 multimer (Fig 5A, lanes 4 -8) . These data further support the hypothesis that DDP mediates cross-links between hCtr1 proteins. Previous studies have demonstrated that the hCtr1 dimer is unstable in the presence of reducing agents, and mutagenic studies suggest that a cytoplasmic cysteine at position 189 may form a disulfide bridge between hCtr1 subunits (24) . To further characterize the DDP-mediated multimerization of hCtr1, we assessed whether the 110-kDa multimer is stable to the presence of the reducing agent dithiothreitol. As expected, the addition of dithiothreitol to protein lysates derived from untreated cells resulted in the marked reduction of the 70-kDa hCtr1 dimer relative to non-reducing conditions (Fig. 5B, compare lane 3 with lane 1) . Significantly, however, pretreatment of the cells with DDP resulted in hCtr1 dimeric and trimeric complexes in the protein lysates that were highly stable in the presence of dithiothreitol (Fig. 5B, compare  lane 2 with lane 4) . These data suggest that the stabilization of the hCtr1 multimer occurs independently of the disulfide bridges between hCtr1 subunits and is largely unaffected by reduction of these bonds.
A notable feature of the hCtr1 protein is two methionine-rich clusters located in the extracellular amino-terminal portion of the molecule (Fig. 6A) . These "Mets" motifs, with the sequences 7 MGMSYM 12 and 40 MMMMPM 45 , are highly conserved among Ctr1 family members from yeast, plants, insects, and mammals (1). The 40 MMMMPM 45 motif closest to the first transmembrane domain of hCtr1 was recently shown to be critical for both the high affinity copper uptake and for stimulating hCtr1 endocytosis in response to low micromolar copper levels (ϳ2 M) (7, 29) . Given the propensity of DDP to bind to the sulfurcontaining amino acids methionine and cysteine (26, 30 -32) , we tested the importance of the Mets motifs in DDP-induced multimerization of hCtr1. Each methionine of both Mets motifs was mutated to alanine resulting in the M1/M2 mutant (Fig.   6A ). DDP treatment of cells resulted in the stabilization of the 110-kDa complex for the wild type hCtr1 protein (Fig. 6B, lane  2) , but no such complex was observed for the M1/M2 mutant protein (Fig. 6B, lane 5) . Immunofluorescence microscopy confirmed that there was abundant expression of the M1/M2 mutant protein at the plasma membrane (Fig. 6A) , suggesting that the absence of a 110-kDa multimer was not because of a defect in trafficking of this mutant protein to the cell surface. Significantly, when the protein cross-linker EGS was added to protein lysates from the M1/M2 mutant cell line, the 110-kDa multimer was readily observed at levels equivalent to the wild type protein (Fig. 6, compare lanes 3 and 6) . This result suggested that although the M1/M2 mutation does not prevent interactions between hCtr1 subunits, it prevents the stabilization of these interactions by DDP. These findings suggest that in the wild type protein, DDP may stabilize interactions between hCtr1 proteins by cross-linking the Mets motifs.
Previous studies in yeast have demonstrated that yCtr1-deficient cells are resistant to a variety of cisplatin analogues (20) , suggesting that these compounds may be transported by the Ctr1 family of transporters. Therefore, we compared the Protein lysates from these cells were then exposed to increasing concentrations of the platinum chelator DDTC for 20 min at 37°C prior to Western blot analysis using anti-myc antibodies. B, HEK/ hCtr1-myc cells were untreated or treated with 300 M DDP to generate the 110-kDa hCtr1 multimer. Protein lysates were then exposed to the reducing agent dithiothreitol or left untreated prior to Western blot analysis using anti-myc antibodies. The predicted positions of monomeric, dimeric, and trimeric hCtr1 complexes are indicated (ovals). Tubulin protein levels in each sample are shown to indicate protein loading.
abilities of DDP and two clinically important cisplatin analogues to induce the multimerization of hCtr1. DDP, carboplatin (cis-diammine-1,1-cyclobutanedicarboxylateplatinum), or oxaliplatin (trans-1-diaminocyclohexane oxalatoplatinum) was supplied to the media of HEK/hCtr1-myc cells at 50 or 500 M for 3 h (Fig. 7) ; this was followed by immunoblot detection of hCtr1-myc protein. Both carboplatin and oxaliplatin treatments resulted in the appearance of the 110-kDa hCtr1 multimer, but this occurred less efficiently relative to DDP, particularly in the case of carboplatin. Neither carboplatin nor oxaliplatin altered the plasma membrane location of hCtr1 in HEK/hCtr1-myc cells (data not shown), as was found earlier for DDP (Fig. 1) . These data suggest that DDP and two of its clinically important analogues are able to stabilize the 110-kDa hCtr1 multimer, albeit with different efficacies.
DISCUSSION
Given the recent finding that the hCtr1 protein undergoes copper-stimulated endocytosis and degradation, we tested whether DDP could elicit a similar posttranslational response. Using two independent approaches involving immunofluorescence microscopy and endocytosis assays, we found no evidence that DDP alters the steady-state distribution or the endocytosis of hCtr1, which remained unchanged in DDP-treated cells. Unexpectedly, DDP exposure resulted in the appearance of a novel 110-kDa hCtr1 multimeric complex, suggesting that DDP may bind to hCtr1 and form cross-links between hCtr1 molecules. This process was rapid and occurred in a dose-dependent manner at minimal DDP concentrations that were similar to plasma concentrations of DDP observed clinically (33, 34) . Previous studies using cross-linking agents and co-immunoprecipitation experiments suggested that Ctr family members in yeast and humans form homodimer and -trimer complexes (3, 4, 35) . The apparent molecular weight of the 110-kDa hCtr1 complex in DDP-treated cells was consistent with a homotrimeric form of hCtr1, but the possibility that this complex results from interactions between hCtr1 and other proteins cannot be excluded by our results. It was notable that carboplatin and oxaliplatin also resulted in the appearance of the hCtr1 multimer because these drugs share little structural similarity to cisplatin beyond their common platinum cores. These findings suggest that it is the platinum ion itself that stabilizes the hCtr1 multimer rather than an indirect pharmacological effect of the drug treatment. Furthermore, the ability of the metal chelator DDTC to disassemble the 110-kDa hCtr1 multimer provided additional evidence that platinum is integral to the structure of this complex. The stabilization of the hCtr1 multimer by DDP is not specific to the HEK293 cell line, as we have observed the same effect in a range of hCtr1-transfected cell lines (data not shown), including A2780 ovarian carcinoma FIG. 6 . DDP-induced multimerization of hCtr1 is dependent on the amino-terminal Mets motifs. A, schematic illustration of the two methionine-rich Mets motifs in the amino-terminal region of hCtr1, in which all methionines were mutated to alanines to generate the M1/M2 mutant. Immunofluorescence microscopy (lower panels) shows the distribution of the wild type and M1/M2 mutant hCtr1 protein in stably transfected HEK293 cells grown in basal medium. B, HEK293 cells stably expressing wild type or M1/M2 mutant hCtr1 protein was exposed to either basal medium or medium containing 500 M DDP for 3 h followed by SDS-PAGE. To generate EGS-cross-linked hCtr1 multimers, cell lysates from basal media-grown cells were treated with 1 mM EGS for 5 min prior to SDS-PAGE. The EGS-and DDP-induced multimerization of hCtr1-myc was assessed by immunoblot analysis using the affinity purified anti-myc antibody followed by anti-mouse secondary antibodies conjugated to HRP. The predicted positions of monomeric, dimeric, and trimeric hCtr1 complexes are indicated (ovals). Tubulin protein levels in each sample are shown to indicate protein loading. cells, in which the exogenous expression of hCtr1 has been shown to increase DDP uptake (22) .
DDP is a neutral molecule consisting of a platinum ion with two ammonia and two chloride ligands. It becomes positively charged when its chloride ions are displaced by water in the plasma or intracellular fluid. In this active form, DDP is able to cross-link DNA strands and selectively bind sulfur-containing amino acids such as cysteine and methionine (36 -40) . Our studies demonstrated that the Mets motifs were critical for the appearance of the 110-kDa hCtr1 multimer in DDP-treated cells but not for multimerization per se, suggesting that DDP may stabilize this complex by cross-linking the Mets motifs of interacting hCtr1 polypeptides. Interestingly, recent yeast twohybrid experiments have shown that individual amino-terminal domains of hCtr1 can interact (41) , suggesting that in principle, the Mets motifs may come close enough to be crosslinked by DDP. It is also notable that DDP has been shown to stabilize the multimeric interactions of the ␣ 2 -macroglobulin and serum albumin (32, 42) and that methionine residues are involved in DDP-induced inter-subunit cross-linking for both proteins (31, 43) .
In contrast to our observation that the endocytosis of hCtr1 is not affected by DDP treatment, DDP has been shown to promote the endocytosis and degradation of yCtr1 in yeast (21) . The reasons for the different effects of DDP on the human and yeast Ctr1 proteins are unclear. Both proteins share only 29% identity, and the yeast orthologue is considerably larger. Moreover, the longer extracellular amino-terminal region of yCtr1 contains eight Mets motifs, compared with only two motifs in the human protein. Perhaps these sequence differences alone may account for the different consequences of DDP on human and yeast orthologues. Alternatively, it is possible that like hCtr1, DDP does indeed promote formation of a multimeric complex of the yCtr1 protein. However, unlike hCtr1, the concomitant stimulation of endocytosis and degradation of this multimer may prevent its detection by immunoblot analysis. Future studies that make use of yeast mutants defective in endocytosis and/or degradation may permit the detection of a cisplatin-stabilized multimer of yCtr1.
The mechanism of hCtr1 transport is not well understood. Although there is evidence to suggest that yCtr1 and hCtr1 form homotrimers, it is currently unclear whether the assembly of such a complex is required for copper transport activity. The hCtr1 polypeptide possesses three putative membrane-spanning regions, and therefore the assembly of a homotrimeric complex should result in a channel consisting of nine transmembrane domains. Our data suggest that DDP may stabilize this trimeric form of hCtr1 by bridging the Mets motifs of interacting hCtr1 subunits. This may facilitate the creation of a pore through which DDP is able to cross the membrane into the cytoplasm, possibly by diffusion down a concentration gradient. Alternatively, others have postulated that the uptake of DDP may be coupled with the endocytosis of a yCtr1-DDP complex (21) , and such a mechanism may also occur for the hCtr1 protein (22) . Our finding that DDP fails to increase hCtr1 endocytosis does not rule out an endocytic mechanism for the uptake of the drug, because endocytosis of hCtr1 still occurs at basal rates in DDP-treated cells (Fig. 2) . Indeed, the uptake of DDP via internalization of an hCtr1-DDP complex to a vesicular compartment is consistent with recent studies in hCtr1-transfected A2780 ovarian carcinoma cells, which suggest that DDP taken up by hCtr1 is restricted from accessing cytotoxic targets like DNA (22) . This endocytic model of DDP uptake is also appealing because it offers an explanation for how the hCtr1 protein can be highly selective for Cu(I) over other divalent metal ions and yet mediate the uptake of DDP, which shares little structural similarity to elemental copper.
In summary, our studies have provided the first evidence for a biochemical interaction between hCtr1 and DDP and have identified candidate DDP-binding sequences in the extracellular region of hCtr1. Further analysis of how DDP stabilizes the multimerization of hCtr1 will provide a more detailed understanding of the mechanism by which hCtr1 mediates DDP uptake and how it differs from that of copper. Our findings highlight potentially valuable new directions for research into candidate platinum-based chemotherapy agents by assessing their propensity to cross-link hCtr1, along with studies examining the abundance and multimeric state of hCtr1 in various tumors and cell lines that respond differently to these agents.
